This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Boehringer Ingelheims performance against key rivals in the prescription pharmaceutical sector
- Evaluate the impact of generic competition for the key product Flomax, particularly in light of recent patent expiry for another key product, Mobic
- Assess how Boehringer could utilize externalization strategies to bolster its long term sales growth and support its internal product development
